In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. CAB-LA is an injectable form of pre-exposure prophylaxis (PrEP) that has been shown to be highly effective at reducing...
As the HIV response moves to focusing on closing the remaining gaps in prevention, testing and treatment services, an evolution in the underlying routine data systems is needed to identify epidemiologic patterns and service gaps, and accelerate focused interventions.
These guidelines focus on the collec...
Cryptococcal disease is one of the most common opportunistic infections among people living with advanced HIV disease and is a major contributor to severe illness, morbidity, and mortality, particularly in sub-Saharan Africa.
These guidelines update the recommendations that were first released in 2018 ...